Search results
Results from the WOW.Com Content Network
The Drug Rebate Equalization Act of 2009 (DRE), introduced in the 111th United States Congress by Representative Bart Stupak as H.R. 904, and in the Senate by Senator Jeff Bingaman as S. 547, sought to equalize the treatment of prescription drug discounts between Medicaid managed care and Medicaid fee-for-service.
It required pharmaceutical manufacturers to provide rebates for medication purchases, based on sales to Medicaid beneficiaries, as a condition of having their products covered by Medicaid. [3] The amount of the rebates paid to the states were based on a "best price" calculation that did not take into account the discounted prices that ...
The Medicaid drug rebate for brand name drugs, paid by drug manufacturers to the states, is increased to 23.1% (except for the rebate for clotting factors and drugs approved exclusively for pediatric use, which increases to 17.1%), and the rebate is extended to Medicaid managed care plans; the Medicaid rebate for non-innovator, multiple source ...
Yet there are gaps in how the billions of taxpayer-supported funding for Medicaid programs in New York addresses maternal health needs. ... About 17% of women ages 18 to 49 on Medicaid who needed ...
Elderly Pharmaceutical Insurance Coverage (EPIC) [1] [2] [3] ("New York State's Senior Prescription Plan") [4] was designed so that personal/out-of-pocket costs for medicines are reduced or largely paid for program participants by the state. [1] Members are also given assistance with Medicare Part D. [5]
The report says about 44% of state residents — including 60% of those in New York City — are covered by Medicaid or the Essential Plan, seven points above any other state. The programs take up ...
New Jersey. New Jersey is sending out $2 billion in property tax rebates to two million of its residents. The amount of the rebate is income-based, with homeowners earning up to $150,000 ...
Ron Wyden stated in April 2019 that they were as “clear a middleman rip-off as you are going to find”, because they make more money when they pick a higher-priced drug over a lower-priced drug. [54] In June 2024, the New York Times released its first article in a series critiquing pharmacy benefit managers for artificially raising drug ...